查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067611

生物模擬市場規模、佔有率和趨勢分析報告：按產品、應用、治療領域、產品模式、定價模式、最終用途、地區和細分市場預測（2026-2033 年）

Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application (Drug Discovery & Development), By Therapeutic Area, By Delivery Model, By Pricing Model, By End-use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 190 Pages | 商品交期: 2-10個工作天內

價格

生物模擬市場概述

全球生物模擬市場預計到 2025 年將達到 41 億美元，到 2026 年將成長至 48 億美元，到 2033 年將達到 148 億美元，2026 年至 2033 年的複合年成長率為 17.3%。

到 2025 年，北美市場將佔銷售額的 44.2%，推動市場成長。

癌症、結核病和其他細菌感染疾病等疾病中抗藥性復發病例的不斷增加，是推動市場成長的主要因素。這些趨勢是市場成長的主要驅動力，並凸顯了將生物模擬技術整合到新一代藥物早期研發階段的重要性。此外，技術進步和軟體升級也提高了研究人員對生物模擬工具的需求，預計這將進一步推動市場成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：生物模擬市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 生物模擬市場分析工具

第4章：生物模擬市場：產品估算與趨勢分析

  • 全球生物模擬市場產品波動分析
  • 全球生物模擬市場：基於產品的規模和趨勢分析，2021-2033年
  • 軟體
    • 分子建模和模擬軟體
    • 臨床試驗設計軟體
    • PK/PD建模與模擬軟體
    • PBPK建模與模擬軟體
    • 毒性預測軟體
    • QSP/系統生物學軟體
    • 其他軟體
  • 服務
    • 合約服務
    • 諮詢
    • 實施、培訓和支持

第5章：生物模擬市場：按應用分類的估算與趨勢分析

  • 全球生物模擬市場：基於應用的波動分析
  • 全球生物模擬市場：基於應用的市場規模與趨勢分析（2021-2033年）
  • 藥物發現與開發
  • 疾病建模
  • 其他領域（精準醫療、毒理學等）

第6章：生物模擬市場：依治療領域分類的估計與趨勢分析

  • 全球生物模擬市場：按治療領域分類的波動分析
  • 全球生物模擬市場：按治療領域分類的規模和趨勢分析（2021-2033年）
  • 腫瘤學
  • 心血管疾病
  • 感染疾病
  • 神經病變
  • 其他

第7章：生物模擬市場：依部署模式分類的估算與趨勢分析

  • 全球生物模擬市場：按部署模式分類的波動分析
  • 全球生物模擬市場：按部署模式分類的規模和趨勢分析（2021-2033年）
  • 基於雲端的
  • 現場
  • 混合模式

第8章：生物模擬市場：基於定價模式的估算與趨勢分析

  • 全球生物模擬市場：基於定價模式的波動分析
  • 全球生物模擬市場：依定價模式的規模與趨勢分析，2021-2033年
  • 基於許可的模式
  • 訂閱模式
  • 基於服務的模式
  • 計量收費模式

第9章：生物模擬市場：依最終用途分類的估算與趨勢分析

  • 全球生物模擬市場：依最終用途分類的波動分析
  • 全球生物模擬市場：終端用戶規模及趨勢分析（2021-2033年）
  • 生命科學公司
    • 製藥公司
    • 生物製藥公司
    • 醫療設備製造商
    • CRO／CDMO
  • 學術研究機構
  • 其他（例如，監管機構）

第10章：生物模擬市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第11章 競爭格局

  • 公司和競爭對手的分類
  • 策略規劃
  • 企業市場分析/市佔率分析，2025年
  • 公司簡介列表
    • Certara, USA.
    • Dassault Systemes
    • Advanced Chemistry Development, Inc.（now a part of Revvity）
    • Simulations Plus
    • Schrodinger, Inc.
    • Chemical Computing Group ULC
    • Physiomics Plc
    • Rosa & Co. LLC
    • BioSimulation Consulting Inc.
    • Genedata AG
    • Instem Group of Companies
    • PPD, Inc.（Acquired by Thermo Fisher Scientific）11.4.13.1. Company overview
    • Yokogawa Insilico Biotechnology GmbH
Product Code: GVR-1-68038-051-4

Biosimulation Market Summary

The global biosimulation market size was valued at USD 4.1 billion in 2025 and is projected to grow from USD 4.8 billion in 2026 to USD 14.8 billion by 2033, at a CAGR of 17.3% from 2026 to 2033. The market in North America dominated with a revenue share of 44.2% in 2025.

This growth is driven by the increasing incidence of drug relapse cases due to drug resistance in diseases such as cancer, tuberculosis, and other bacterial infections. These trends are key drivers of market growth, underscoring the critical need to integrate biosimulation into the early development of a new generation of drugs. In addition, the rising demand for biosimulation tools among researchers, fueled by technological advancements and software upgrades, is expected to further enhance market growth.

Global Biosimulation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biosimulation market report based on product, application, therapeutic area, deployment model, pricing model, end use, and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Software
    • Molecular Modeling & Simulation Software
    • Docking, molecular dynamics, QSAR
    • Small Molecules
    • Biologics
    • In-silico ADME (ChemAxon-type tools)
    • Large Pharma (Top ~30)
    • Mid Pharma (~30-300)
    • Emerging / Long-tail Pharma & Biotech
    • Physicochemical property prediction (logP, pKa, solubility, permeability)
    • Clinical Trial Design Software
    • Clinical trial simulation
    • Adaptive design
    • Virtual patients
    • Dose optimization
    • MIDD-linked applications
    • PK/PD Modeling and Simulation Software
    • Software
    • Compartmental modeling
    • Population PK/PD (Pop PK/PD)
    • Non-compartmental analysis (NCA)
    • Dose-response, bioequivalence
    • Customer
    • Large Pharma (Top ~30)
    • Mid Pharma (~30-300)
    • Emerging / Long-tail Pharma & Biotech
    • Pbpk Modeling and Simulation Software
    • ADME (mechanistic)
    • DDI modeling
    • FIH dose prediction
    • Special populations
    • Toxicity Prediction Software
    • Hepatotoxicity, cardiotoxicity, genotoxicity
    • QSAR, mechanistic, AI/ML models
    • ADME-linked toxicity
    • QSP / Systems Biology Software
    • Software
    • Mechanistic disease modeling
    • Multi-scale simulation
    • Integration with PBPK
    • Customer
    • Large Pharma (Top ~30)
    • Mid Pharma (~30-300)
    • Emerging / Long-tail Pharma & Biotech
    • Other Software
    • AI-driven platforms
    • RWD-integrated tools
  • Services
    • Contract Services
    • Services
    • PK/PD services
    • Pop PK/PD
    • NCA
    • Compartmental
    • PBPK services
    • ADME
    • DDI
    • Special populations
    • Customer
    • Large Pharma (Top ~30)
    • Mid Pharma (~30-300)
    • Emerging / Long-tail Pharma & Biotech
    • Consulting
    • Large Pharma (Top ~30)
    • Mid Pharma (~30-300)
    • Emerging / Long-tail Pharma & Biotech
    • Implementation, Training & Support
    • Service
    • Deployment
    • Integration
    • Training
    • Customer
    • Large Pharma (Top ~30)
    • Mid Pharma (~30-300)
    • Emerging / Long-tail Pharma & Biotech
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Discovery & Development
  • Disease Modeling
  • Other (Precision Medicine, Toxicology, etc., etc.)
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Cardiovascular Disease
  • Infectious Disease
  • Neurological Disorders
  • Others
  • Deployment Model Outlook (Revenue, USD Million, 2021 - 2033)
  • Cloud-based
  • On-premise
  • Hybrid Model
  • Pricing Model Outlook (Revenue, USD Million, 2021 - 2033)
  • License-based Model
  • Subscription-based Model
  • Service-based Model
  • Pay Per Use Model
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Life Sciences Companies
    • Pharmaceutical Companies
    • Biopharma Companies
    • Medical Device Companies
    • CROs/CDMOs
  • Academic Research Institutions
  • Others (Regulatory Authorities, etc.)
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. Therapeutic Area Segment
    • 1.2.4. Deployment Model Segment
    • 1.2.5. Pricing Model Segment
    • 1.2.6. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Biosimulation Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising adoption of Model-Informed Drug Development
      • 3.2.1.2. Growing demand for personalized medicine
      • 3.2.1.3. Expansion of pharmaceutical and biotechnology R&D investments
      • 3.2.1.4. Increasing complexity of drug pipelines
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost associated with biosimulation technology and software
      • 3.2.2.2. Stringent regulatory requirements
    • 3.2.3. Case study Insights
    • 3.2.4. Emerging Technologies
  • 3.3. Biosimulation Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal Landscape
      • 3.3.2.6. Social Landscape

Chapter 4. Bio simulation Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global bio simulation Market Product Movement Analysis
  • 4.3. Global Biosimulation Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Software
    • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Molecular Modeling & Simulation Software
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.2. Docking, molecular dynamics, QSAR
        • 4.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.2.2. Small Molecules
          • 4.4.2.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.2.3. Biologics
          • 4.4.2.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.3. In-silico ADME (e.g., ChemAxon-type tools)
        • 4.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.2. Large Pharma (Top ~30)
          • 4.4.2.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.3. Mid Pharma (~30-300)
          • 4.4.2.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.4. Emerging / Long-tail Pharma & Biotech
          • 4.4.2.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.4. Physicochemical property prediction (logP, pKa, solubility, permeability)
    • 4.4.3. Clinical Trial Design Software
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.3.2. Clinical trial simulation
        • 4.4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.3.3. Adaptive design
        • 4.4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.3.4. Virtual patients
        • 4.4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.3.5. Dose optimization
        • 4.4.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.3.6. MIDD-linked applications
        • 4.4.3.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. PK/PD Modeling and Simulation Software
      • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.4.2. Software
        • 4.4.4.2.1. Compartmental modeling
          • 4.4.4.2.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.4.2.2. Population PK/PD (Pop PK/PD)
          • 4.4.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.4.2.3. Non-compartmental analysis (NCA)
          • 4.4.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.4.2.4. Dose-response, bioequivalence
          • 4.4.4.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.4.3. Customer
        • 4.4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.4.3.2. Large Pharma (Top ~30)
          • 4.4.4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.4.3.3. Mid Pharma (~30-300)
          • 4.4.4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.4.3.4. Emerging / Long-tail Pharma & Biotech
          • 4.4.4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Pbpk Modeling and Simulation Software
      • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.5.2. ADME (mechanistic)
        • 4.4.5.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.5.3. DDI modeling
        • 4.4.5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.5.4. FIH dose prediction
        • 4.4.5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.5.5. Special populations
        • 4.4.5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6. Toxicity Prediction Software
      • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.6.2. Hepatotoxicity, cardiotoxicity, genotoxicity
        • 4.4.6.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.6.3. QSAR, mechanistic, AI/ML models
        • 4.4.6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.6.4. ADME-linked toxicity
        • 4.4.6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7. QSP / Systems Biology Software
      • 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.7.2. Software
        • 4.4.7.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.7.2.2. Mechanistic disease modeling
          • 4.4.7.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.7.2.3. Multi-scale simulation
          • 4.4.7.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.7.2.4. Integration with PBPK
          • 4.4.7.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.7.3. Customer
        • 4.4.7.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.7.3.2. Large Pharma (Top ~30)
          • 4.4.7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.7.3.3. Mid Pharma (~30-300)
          • 4.4.7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.7.3.4. Emerging / Long-tail Pharma & Biotech
          • 4.4.7.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8. Other Software
      • 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.8.2. AI-driven platforms
        • 4.4.8.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.8.3. RWD-integrated tools
        • 4.4.8.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Services
    • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2. Contract Services
      • 4.5.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.2.2. Services
        • 4.5.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.2.2.2. PK/PD services
          • 4.5.2.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.5.2.2.2.1.1. Pop PK/PD Services
              • 4.5.2.2.2.1.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.5.2.2.2.1.2. NCA
              • 4.5.2.2.2.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.5.2.2.2.1.3. Compartmental
              • 4.5.2.2.2.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.5.2.2.2.1.4. PBPK Services
              • 4.5.2.2.2.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
              • 4.5.2.2.2.1.4.2. ADME
            • 4.5.2.2.2.1.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
              • 4.5.2.2.2.1.4.3. DDI
            • 4.5.2.2.2.1.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
              • 4.5.2.2.2.1.4.4. Special populations
            • 4.5.2.2.2.1.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.2.3. Customer
        • 4.5.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.2.3.2. Large Pharma (Top ~30)
          • 4.5.2.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.2.3.3. Mid Pharma (~30-300)
          • 4.5.2.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.2.3.4. Emerging / Long-tail Pharma & Biotech
          • 4.5.2.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3. Consulting
      • 4.5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.3.2. Large Pharma (Top ~30)
        • 4.5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.3.2.2. Mid Pharma (~30-300)
        • 4.5.3.2.3. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.3.2.4. Emerging / Long-tail Pharma & Biotech
          • 4.5.3.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.4. Implementation, Training & Support
      • 4.5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.4.2. Service
        • 4.5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.4.2.2. Deployment
          • 4.5.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.4.2.3. Integration
          • 4.5.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.4.2.4. Training
          • 4.5.4.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.4.3. Customer
        • 4.5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.4.3.2. Large Pharma (Top ~30)
          • 4.5.4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.4.3.3. Mid Pharma (~30-300)
          • 4.5.4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.5.4.3.4. Emerging / Long-tail Pharma & Biotech
          • 4.5.4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Biosimulation Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biosimulation Market Application Movement Analysis
  • 5.3. Global Biosimulation Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Drug Discovery & Development
    • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Disease Modeling
    • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Other (Precision Medicine, Toxicology, etc., etc.)
    • 5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Biosimulation Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biosimulation Market Therapeutic Area Movement Analysis
  • 6.3. Global Biosimulation Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Cardiovascular Disease
    • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Infectious Disease
    • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Neurological Disorders
    • 6.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Biosimulation Market: Deployment Model Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Biosimulation Market Deployment Model Movement Analysis
  • 7.3. Global Biosimulation Market Size & Trend Analysis, by Deployment Model, 2021 to 2033 (USD Million)
  • 7.4. Cloud-based
    • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. On-premises
    • 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Hybrid Model
    • 7.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Biosimulation Market: Pricing Model Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Biosimulation Market Pricing Model Movement Analysis
  • 8.3. Global Biosimulation Market Size & Trend Analysis, by Pricing Model, 2021 to 2033 (USD Million)
  • 8.4. License-based Model
    • 8.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Subscription-based Model
    • 8.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Service-based Model
    • 8.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Pay Per Use Model
    • 8.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Biosimulation Market: End Use Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Biosimulation Market End Use Movement Analysis
  • 9.3. Global Biosimulation Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 9.4. Life Science Companies
    • 9.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.2. Pharmaceutical Companies
      • 9.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.3. Biopharma Companies
      • 9.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.4. Medical Device Companies
      • 9.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.5. CROs/CDMOs
      • 9.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5. Academic Research Institutions
    • 9.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6. Others (Regulatory Authorities, etc.)
    • 9.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Biosimulation Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2025 & 2033
  • 10.2. Regional Market Dashboard
  • 10.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 10.4. North America
    • 10.4.1. U.S.
      • 10.4.1.1. Key country dynamics
      • 10.4.1.2. Regulatory framework
      • 10.4.1.3. Competitive scenario
      • 10.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.4.2. Canada
      • 10.4.2.1. Key country dynamics
      • 10.4.2.2. Regulatory framework
      • 10.4.2.3. Competitive scenario
      • 10.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.4.3. Mexico
      • 10.4.3.1. Key country dynamics
      • 10.4.3.2. Regulatory framework
      • 10.4.3.3. Competitive scenario
      • 10.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.5. Europe
    • 10.5.1. UK
      • 10.5.1.1. Key country dynamics
      • 10.5.1.2. Regulatory framework
      • 10.5.1.3. Competitive scenario
      • 10.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.5.2. Germany
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.5.3. France
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Regulatory framework
      • 10.5.3.3. Competitive scenario
      • 10.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.5.4. Italy
      • 10.5.4.1. Key country dynamics
      • 10.5.4.2. Regulatory framework
      • 10.5.4.3. Competitive scenario
      • 10.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.5.5. Spain
      • 10.5.5.1. Key country dynamics
      • 10.5.5.2. Regulatory framework
      • 10.5.5.3. Competitive scenario
      • 10.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.5.6. Norway
      • 10.5.6.1. Key country dynamics
      • 10.5.6.2. Regulatory framework
      • 10.5.6.3. Competitive scenario
      • 10.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.5.7. Sweden
      • 10.5.7.1. Key country dynamics
      • 10.5.7.2. Regulatory framework
      • 10.5.7.3. Competitive scenario
      • 10.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.5.8. Denmark
      • 10.5.8.1. Key country dynamics
      • 10.5.8.2. Regulatory framework
      • 10.5.8.3. Competitive scenario
      • 10.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Japan
      • 10.6.1.1. Key country dynamics
      • 10.6.1.2. Regulatory framework
      • 10.6.1.3. Competitive scenario
      • 10.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.2. China
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.3. India
      • 10.6.3.1. Key country dynamics
      • 10.6.3.2. Regulatory framework
      • 10.6.3.3. Competitive scenario
      • 10.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.4. Australia
      • 10.6.4.1. Key country dynamics
      • 10.6.4.2. Regulatory framework
      • 10.6.4.3. Competitive scenario
      • 10.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.5. South Korea
      • 10.6.5.1. Key country dynamics
      • 10.6.5.2. Regulatory framework
      • 10.6.5.3. Competitive scenario
      • 10.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.6. Thailand
      • 10.6.6.1. Key country dynamics
      • 10.6.6.2. Regulatory framework
      • 10.6.6.3. Competitive scenario
      • 10.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Brazil
      • 10.7.1.1. Key country dynamics
      • 10.7.1.2. Regulatory framework
      • 10.7.1.3. Competitive scenario
      • 10.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.7.2. Argentina
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.8. MEA
    • 10.8.1. South Africa
      • 10.8.1.1. Key country dynamics
      • 10.8.1.2. Regulatory framework
      • 10.8.1.3. Competitive scenario
      • 10.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.8.2. Saudi Arabia
      • 10.8.2.1. Key country dynamics
      • 10.8.2.2. Regulatory framework
      • 10.8.2.3. Competitive scenario
      • 10.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.8.3. UAE
      • 10.8.3.1. Key country dynamics
      • 10.8.3.2. Regulatory framework
      • 10.8.3.3. Competitive scenario
      • 10.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.8.4. Kuwait
      • 10.8.4.1. Key country dynamics
      • 10.8.4.2. Regulatory framework
      • 10.8.4.3. Competitive scenario
      • 10.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company/Competition Categorization
  • 11.2. Strategy Mapping
  • 11.3. Company Market Position/Share Analysis, 2025
  • 11.4. Company Profiles/Listing
    • 11.4.1. Certara, USA.
      • 11.4.1.1. Company overview
      • 11.4.1.2. Financial performance
      • 11.4.1.3. Product benchmarking
      • 11.4.1.4. Strategic initiatives
    • 11.4.2. Dassault Systemes
      • 11.4.2.1. Company overview
      • 11.4.2.2. Financial performance
      • 11.4.2.3. Product benchmarking
      • 11.4.2.4. Strategic initiatives
    • 11.4.3. Advanced Chemistry Development, Inc. (now a part of Revvity )
      • 11.4.3.1. Company overview
      • 11.4.3.2. Financial performance
      • 11.4.3.3. Product benchmarking
      • 11.4.3.4. Strategic initiatives
    • 11.4.4. Simulations Plus
      • 11.4.4.1. Company overview
      • 11.4.4.2. Financial performance
      • 11.4.4.3. Product benchmarking
      • 11.4.4.4. Strategic initiatives
    • 11.4.5. Schrodinger, Inc.
      • 11.4.5.1. Company overview
      • 11.4.5.2. Financial performance
      • 11.4.5.3. Product benchmarking
      • 11.4.5.4. Strategic initiatives
    • 11.4.6. Chemical Computing Group ULC
      • 11.4.6.1. Company overview
      • 11.4.6.2. Financial performance
      • 11.4.6.3. Product benchmarking
      • 11.4.6.4. Strategic initiatives
    • 11.4.7. Physiomics Plc
      • 11.4.7.1. Company overview
      • 11.4.7.2. Financial performance
      • 11.4.7.3. Product benchmarking
      • 11.4.7.4. Strategic initiatives
    • 11.4.8. Rosa & Co. LLC
      • 11.4.8.1. Company overview
      • 11.4.8.2. Financial performance
      • 11.4.8.3. Product benchmarking
      • 11.4.8.4. Strategic initiatives
    • 11.4.9. BioSimulation Consulting Inc.
      • 11.4.9.1. Company overview
      • 11.4.9.2. Financial performance
      • 11.4.9.3. Product benchmarking
      • 11.4.9.4. Strategic initiatives
    • 11.4.10. Genedata AG
      • 11.4.10.1. Company overview
      • 11.4.10.2. Financial performance
      • 11.4.10.3. Product benchmarking
      • 11.4.10.4. Strategic initiatives
    • 11.4.11. Instem Group of Companies
      • 11.4.11.1. Company overview
      • 11.4.11.2. Financial performance
      • 11.4.11.3. Product benchmarking
      • 11.4.11.4. Strategic initiatives
    • 11.4.12. PPD, Inc. (Acquired by Thermo Fisher Scientific)11.4.13.1. Company overview
      • 11.4.12.1. Company overview
      • 11.4.12.2. Financial performance
      • 11.4.12.3. Product benchmarking
      • 11.4.12.4. Strategic initiatives
    • 11.4.13. Yokogawa Insilico Biotechnology GmbH
      • 11.4.13.1. Company overview
      • 11.4.13.2. Financial performance
      • 11.4.13.3. Product benchmarking
      • 11.4.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global biosimulation market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 4 Global biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 5 Global biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 6 Global biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 7 Global biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 8 Global biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 9 North America biosimulation market, by country, 2021 - 2033 (USD Million)
  • Table 10 North America biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 11 North America biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 12 North America biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 13 North America biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 14 North America biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 15 North America biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 16 U.S. biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 17 U.S. biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 18 U.S. biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 19 U.S. biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 20 U.S. biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 21 U.S. biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 22 Canada biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 23 Canada biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 24 Canada biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 25 Canada biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 26 Canada biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 27 Canada biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Mexico biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 29 Mexico biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 30 Mexico biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 31 Mexico biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 32 Mexico biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 33 Mexico biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Europe biosimulation market, by country, 2021 - 2033 (USD Million)
  • Table 35 Europe biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 36 Europe biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 37 Europe biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 38 Europe biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 39 Europe biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 40 Europe biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 41 UK biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 42 UK biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 43 UK biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 44 UK biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 45 UK biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 46 UK biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Germany biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 48 Germany biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 49 Germany biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 50 Germany biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 51 Germany biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 52 Germany biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 53 France biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 54 France biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 55 France biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 56 France biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 57 France biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 58 France biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Italy biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 60 Italy biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 61 Italy biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 62 Italy biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 63 Italy biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 64 Italy biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Spain biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 66 Spain biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 67 Spain biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 68 Spain biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 69 Spain biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 70 Spain biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Denmark biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 72 Denmark biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 73 Denmark biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 74 Denmark biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 75 Denmark biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 76 Denmark biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 77 Sweden biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 78 Sweden biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 79 Sweden biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 80 Sweden biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 81 Sweden biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 82 Sweden biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Norway biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 84 Norway biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 85 Norway biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 86 Norway biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 87 Norway biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 88 Norway biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 89 Asia Pacific biosimulation market, by country, 2021 - 2033 (USD Million)
  • Table 90 Asia Pacific biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 91 Asia Pacific biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 92 Asia Pacific biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 93 Asia Pacific biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 94 Asia Pacific biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 95 Asia Pacific biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 96 China biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 97 China biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 98 China biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 99 China biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 100 China biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 101 China biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 102 Japan biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 103 Japan biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 104 Japan biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 105 Japan biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 106 Japan biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 107 Japan biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 108 India biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 109 India biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 110 India biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 111 India biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 112 India biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 113 India biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 114 South Korea biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 115 South Korea biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 116 South Korea biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 117 South Korea biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 118 South Korea biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 119 South Korea biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 120 Australia biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 121 Australia biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 122 Australia biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 123 Australia biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 124 Australia biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 125 Australia biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 126 Thailand biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 127 Thailand biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 128 Thailand biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 129 Thailand biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 130 Thailand biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 131 Thailand biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 132 Latin America biosimulation market, by country, 2021 - 2033 (USD Million)
  • Table 133 Latin America biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 134 Latin America biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 135 Latin America biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 136 Latin America biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 137 Latin America biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 138 Latin America biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 139 Brazil biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 140 Brazil biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 141 Brazil biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 142 Brazil biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 143 Brazil biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 144 Brazil biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 145 Argentina biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 146 Argentina biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 147 Argentina biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 148 Argentina biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 149 Argentina biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 150 Argentina biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 151 MEA biosimulation market, by country, 2021 - 2033 (USD Million)
  • Table 152 MEA biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 153 MEA biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 154 MEA biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 155 MEA biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 156 MEA biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 157 MEA biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 158 South Africa biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 159 South Africa biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 160 South Africa biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 161 South Africa biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 162 South Africa biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 163 South Africa biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 164 Saudi Arabia biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 165 Saudi Arabia biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 166 Saudi Arabia biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 167 Saudi Arabia biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 168 Saudi Arabia biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 169 Saudi Arabia biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 170 UAE biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 171 UAE biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 172 UAE biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 173 UAE biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 174 UAE biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 175 UAE biosimulation market, by end use, 2021 - 2033 (USD Million)
  • Table 176 Kuwait biosimulation market, by product, 2021 - 2033 (USD Million)
  • Table 177 Kuwait biosimulation market, by application, 2021 - 2033 (USD Million)
  • Table 178 Kuwait biosimulation market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 179 Kuwait biosimulation market, by deployment model, 2021 - 2033 (USD Million)
  • Table 180 Kuwait biosimulation market, by pricing model, 2021 - 2033 (USD Million)
  • Table 181 Kuwait biosimulation market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Biosimulation market: Market outlook
  • Fig. 5 Biosimulation market: Segment outlook
  • Fig. 6 Biosimulation market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Biosimulation market driver impact
  • Fig. 9 Biosimulation market restraint impact
  • Fig. 10 Biosimulation market: Product outlook and key takeaways
  • Fig. 11 Biosimulation market: Product movement analysis
  • Fig. 12 Software market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 13 Molecular modeling & simulation software market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 14 Clinical trial design software market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 15 PK/PD modeling and simulation software market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 Pbpk modeling and simulation software market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 Toxicity prediction software market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 Other software market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Services market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Contract services market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Consulting services market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Other services market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Biosimulation market: Application outlook and key takeaways
  • Fig. 24 Biosimulation market: Application movement analysis
  • Fig. 25 Drug discovery & development market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Disease modeling market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Biosimulation market: Therapeutic area outlook and key takeaways
  • Fig. 29 Biosimulation market: Therapeutic area movement analysis
  • Fig. 30 Oncology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Cardiovascular disease modeling market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Infectious disease modeling market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Neurological disorders modeling market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Biosimulation market: Deployment model outlook and key takeaways
  • Fig. 36 Biosimulation market: Deployment model movement analysis
  • Fig. 37 Cloud-based market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 On-premises market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Hybrid market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Biosimulation market: Pricing model outlook and key takeaways
  • Fig. 41 Biosimulation market: Pricing model movement analysis
  • Fig. 42 License-based model market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Subscription-based model market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Service-based model market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Pay-per-use model market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Biosimulation market: End use outlook and key takeaways
  • Fig. 47 Biosimulation market: End use movement analysis
  • Fig. 48 Life Science companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Pharmaceutical companies' market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 50 Biopharma companies market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 51 Medical device companies market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 52 CROs/CDMOs market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 53 Academic institutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Others market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 55 Global biosimulation market: Regional outlook and key takeaways
  • Fig. 56 Global biosimulation market: Regional movement analysis
  • Fig. 57 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 99 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)